TYLER CAPITAL LIMITED

1. Financial Health Score: D

Explanation: Tyler Capital Limited is exhibiting severe symptoms of financial distress. The company is suffering from a chronic "revenue deficiency," having bled out substantial operating losses in both the current and prior years. While the patient still has a strong bone marrow reserve (net assets of £10.3M), the dramatic hemorrhage of cash reserves (an 80% drop over two years) and reliance on non-binding shareholder life support to meet going concern criteria indicate a critical condition. Aggressive emergency surgery has been performed, but the business remains in intensive care.

2. Key Vital Signs

• Cash Reserves (Blood Pressure): £2.32M This is the most alarming vital sign. Healthy cash flow is the lifeblood of any trading firm, and Tyler Capital’s cash has plummeted from £12M in 2020 to just £2.3M. This severe drop in blood pressure indicates the company is burning through its liquidity at a dangerous rate to fund operations and trading margins.
• Operating Loss (Fever): -£6.0M The business is running a high, persistent fever. While the operating loss has cooled slightly from the previous year’s -£7.4M, the core business model is currently failing to generate positive organic health.
• Net Assets (Bone Density): £10.28M Despite the losses, the company still has substantial underlying strength. Net assets have declined from £15.4M in 2020, meaning the company is losing muscle mass, but it is not yet insolvent. The balance sheet remains the primary source of resilience.
• Liabilities (Cholesterol): £541k This is a positive vital sign. The company has successfully cleared its arteries, reducing total liabilities by over 70% from £2.2M in 2020. This significantly lowers the risk of a sudden, fatal blockage.
• Dividend Payout (Blood Transfusion Out): £801k A highly irregular symptom. Paying out over £800k in dividends while suffering a £3.8M net loss and rapidly depleting cash is akin to donating blood while actively hemorrhaging. This defies standard financial wellness practices.

3. Diagnosis

The patient is suffering from Acute Profitability Deficiency complicated by Severe Cash Flow Hemorrhage, but is currently in Post-Restructuring Recovery.

The underlying business health is currently poor. The proprietary trading models—the "heart" of the business—are failing to pump sufficient revenue into the system, resulting in consecutive years of heavy trading losses. This has forced the company to consume its own cash reserves to survive.

However, management has recognized the severity of the illness and has performed major emergency surgery. Over the past year, they have: 1. Amputated over 40% of staff to reduce the metabolic burn rate (overheads). 2. Excised a long-term lease commitment. 3. Reduced market exposure to lower the risk of a fatal trading shock. 4. Returned £2M of equity capital in March 2022, suggesting they believed it was surplus to margin requirements, though this coincides with the period of heavy cash burn.

The most concerning symptom in the medical chart is the Going Concern Warning. The directors explicitly state that the company relies on "non-binding assurances from their shareholders that more financial support will be available if needed" to continue trading. This means the patient is currently relying on the promise of an external life-support system that is not legally guaranteed.

4. Recommendations

To stabilize the patient and restore long-term financial wellness, the following immediate interventions are required:

• Secure Binding Financial Life Support: Relying on non-binding shareholder assurances is a high-risk treatment plan. The company must immediately convert these assurances into formal, legally binding commitments (such as a committed overdraft facility or a formal letter of support) to ensure the cash flow doesn't flatline.
• Halt Dividend "Bleeding": It is medically inadvisable to continue distributing dividends while the company is generating operational losses and depleting cash. All available cash must be retained in the system to bolster working capital and fund trading margins.
• Intensive Cash Flow Monitoring: With cash reserves at £2.3M in a highly volatile trading environment, the "pulse" must be monitored daily. Management must establish strict cash-flow forecasting to ensure margin requirements can be met without forced liquidation of positions.
• Rehabilitate the Trading Models: The long-term prognosis depends entirely on whether the machine learning models can be rehabilitated to generate stable income. R&D investment must be strictly focused on strategies that yield a reliable, low-volatility return, moving away from the market exposures that caused the recent heavy losses.
• Monitor Regulatory Side Effects: As an FCA-regulated entity, the reduction in capital and ongoing losses could trigger regulatory thresholds. Management must ensure they maintain adequate capital resources to avoid regulatory intervention, which could effectively place the company into receivership.